<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="openVirus\examples\priya950\4-part\PMC7266814\results\search\disease\results.xml">
  <result pre="CD137 costimulation enhances the antiviral activity of Vγ9Vδ2-T cells against" exact="influenza" post="virus PeiYujunWenKunXiangZhengHuangChunyuWangXiweiMuXiaofengWenLiyanLiuYinpingTuWenweiwwtu@hku.hk[], 0000000121742757grid.194645.bDepartment of Paediatrics and Adolescent Medicine, Li"/>
  <result pre="vaccines and antiviral drugs have achieved great advances in controlling" exact="influenza" post="virus infection, the efficacy of these strategies is limited"/>
  <result pre="pamidronate could be a therapeutic strategy to treat seasonal and" exact="avian influenza" post="virus infections. However, one notable drawback of γδ-T cell-based"/>
  <result pre="could be a therapeutic strategy to treat seasonal and avian" exact="influenza" post="virus infections. However, one notable drawback of γδ-T cell-based"/>
  <result pre="stimulation. CD137+ Vγ9Vδ2-T cells displayed more potent antiviral activity against" exact="influenza" post="virus than their CD137− counterparts in vitro and in"/>
  <result pre="human CD137L protein boosted the therapeutic effects of pamidronate against" exact="influenza" post="virus. Our study provides a novel strategy of targeting"/>
  <result pre="vaccines and antiviral drugs have achieved great advances in controlling" exact="influenza" post="virus infection, the efficacy of these strategies is still"/>
  <result pre="immunity was recently thought to have obvious advantages in controlling" exact="influenza" post="infection without the risks of viral mutation and antiviral"/>
  <result pre="and zoledronate, which are commonly used for the treatment of" exact="osteoporosis" post="and Paget’s disease, can induce the activation and expansion"/>
  <result pre="that phosphoantigen-activated Vγ9Vδ2-T cells have antiviral activities against human and" exact="avian influenza" post="viruses mediated by killing virus-infected monocyte-derived macrophages (MDMs), inhibiting"/>
  <result pre="phosphoantigen-activated Vγ9Vδ2-T cells have antiviral activities against human and avian" exact="influenza" post="viruses mediated by killing virus-infected monocyte-derived macrophages (MDMs), inhibiting"/>
  <result pre="virus-specific antibodies.16–20 Recently, we further reported that PAM can control" exact="influenza" post="diseases by expanding the Vγ9Vδ2-T cell population in humanized"/>
  <result pre="mice.21,22 However, the application of PAM for the treatment of" exact="influenza" post="is limited by the rapid exhaustion of the proliferation"/>
  <result pre="have been shown to enhance the efficacy of vaccines against" exact="influenza" post="virus and poxvirus by enhancing CD8+ or CD4+ T"/>
  <result pre="survival and effector functions of Vγ9Vδ2-T cells in response to" exact="influenza" post="virus infection in vitro and in vivo. Using a"/>
  <result pre="that SA-hCD137L is an efficient adjuvant for PAM therapy for" exact="influenza" post="virus infection that functions by improving the antiviral activity"/>
  <result pre="CD137 on Vγ9Vδ2-T cells while coculturing PAM-expanded Vγ9Vδ2-T cells with" exact="influenza" post="H1N1/A/PR/8/34 virus-infected autologous MDMs. CD137 was rapidly induced in"/>
  <result pre="Vγ9Vδ2-T cells became CD137+ cells after 24 h of coculture with" exact="influenza" post="virus-infected MDMs (Fig. 1c). Importantly, CD137L expression was also"/>
  <result pre="25.7 ± 4.3% of the MDMs became CD137L+ cells after 24 h of" exact="influenza" post="virus infection (Fig. 1d). These data indicated that the"/>
  <result pre="CD137L were upregulated on Vγ9Vδ2-T cells and MDMs, respectively, during" exact="influenza" post="virus infection, raising the possibility that CD137/CD137L could serve"/>
  <result pre="on Vγ9Vδ2-T cells was detected during coculture with mock- or" exact="influenza" post="virus-infected autologous MDMs for the indicated time. d CD137L"/>
  <result pre="d CD137L expression on MDMs was evaluated during mock or" exact="influenza" post="virus infection. Cells were harvested at the indicated time"/>
  <result pre="**p &amp;lt; 0.01 CD137+ Vγ9Vδ2-T cells had more potent antiviral activity against" exact="influenza" post="virus than their CD137− counterparts in vitro We further"/>
  <result pre="function of CD137+ and CD137- Vγ9Vδ2-T cells during coculture with" exact="influenza" post="virus-infected MDMs. As shown in Fig. 2a, CD137+ Vγ9Vδ2-T"/>
  <result pre="CD137+ Vγ9Vδ2-T cells than CD137- Vγ9Vδ2-T cells after coculture with" exact="influenza" post="virus-infected MDMs (Fig. 2a), which suggested that influenza virus-infected"/>
  <result pre="coculture with influenza virus-infected MDMs (Fig. 2a), which suggested that" exact="influenza" post="virus-infected MDMs triggered more intensive granule release from CD137+"/>
  <result pre="2 CD137+ Vγ9Vδ2-T Cells had more potent antiviral activity against" exact="influenza" post="virus than their CD137− counterparts in vitro. a, b"/>
  <result pre="counterparts in vitro. a, b Human MDMs were infected with" exact="influenza" post="virus at an MOI of 2 for 1h and"/>
  <result pre="6h. Then, these cells (effector cells, E) were cocultured with" exact="influenza" post="virus-infected autologous MDMs (target cells, T) at an E:T"/>
  <result pre="sorted these two subsets and detected their cytotoxic activity against" exact="influenza" post="virus-infected MDMs. As shown in Fig. 2c, both CD137+"/>
  <result pre="antiviral activities of both CD137+ and CD137− Vγ9Vδ2-T cells against" exact="influenza" post="virus in vivo, Rag2−/− γc−/− mice were infected with"/>
  <result pre="influenza virus in vivo, Rag2−/− γc−/− mice were infected with" exact="influenza" post="virus intranasally (i.n.). CD137+ and CD137− Vγ9Vδ2-T cell subsets"/>
  <result pre="CD137− or whole Vγ9Vδ2-T cells were adoptively transferred into the" exact="influenza" post="virus-infected mice on days 2, 4, and 6 post"/>
  <result pre="Treatment with CD137+ Vγ9Vδ2-T cells showed more efficacy in controlling" exact="influenza" post="disease than CD137- and whole Vγ9Vδ2-T cells, with the"/>
  <result pre="that CD137+ Vγ9Vδ2-T cells displayed superior antiviral effects in controlling" exact="influenza" post="disease in vivo. Fig. 3 CD137+ Vγ9Vδ2-T cells had"/>
  <result pre="evaluation of the therapeutic effect of Vγ9Vδ2-T cell subsets on" exact="influenza" post="virus-infected Rag2−/− γc−/− mice. Rag2−/− γc−/− mice were infected"/>
  <result pre="Rag2−/− γc−/− mice were infected with a sublethal dose of" exact="influenza" post="virus (25μl, 104 TCID50) intranasally (i.n.) on day 0."/>
  <result pre="CD137 costimulation enhanced the antiviral activity of Vγ9Vδ2-T cells against" exact="influenza" post="virus We have shown that CD137+ Vγ9Vδ2-T cells display"/>
  <result pre="SA-hCD137L protein to a coculture of whole Vγ9Vδ2-T cells with" exact="influenza" post="virus-infected MDMs significantly enhanced the expression of CD107a, cytolytic"/>
  <result pre="recombinant protein significantly increased the cytotoxicity of Vγ9Vδ2-T cells against" exact="influenza" post="virus-infected MDMs (Fig. 4b). These data demonstrated that CD137"/>
  <result pre="CD137 costimulation enhanced the antiviral activity of Vγ9Vδ2-T cells against" exact="influenza" post="virus. Human MDMs (target cells, T) were infected with"/>
  <result pre="of CD137 in the antiviral activity of Vγ9Vδ2-T cells against" exact="influenza" post="virus, an anti-CD137 neutralizing mAb was used to block"/>
  <result pre="costimulation could enhance the antiviral activity of Vγ9Vδ2-T cells against" exact="influenza" post="virus. CD137 costimulation promoted the proliferation and prolonged the"/>
  <result pre="difference CD137 costimulation improved the therapeutic effect of PAM against" exact="influenza" post="virus infection in vivo To demonstrate whether costimulation through"/>
  <result pre="can improve the therapeutic effect of PAM-expanded Vγ9Vδ2-T cells against" exact="influenza" post="virus in vivo, humanized mice reconstituted with whole huPBMC"/>
  <result pre="with the recombinant SA-hCD137L protein and PAM 3 days after" exact="influenza" post="virus infection (Fig. 6a). During the 20 days of"/>
  <result pre="whether the effect of SA-hCD137L costimulation on the control of" exact="influenza" post="virus infection in humanized mice was mediated by Vγ9Vδ2-T"/>
  <result pre="SA-hCD137L protein had a synergistic effect with PAM to control" exact="influenza" post="disease in vivo and that their antiviral activity against"/>
  <result pre="influenza disease in vivo and that their antiviral activity against" exact="influenza" post="virus was mainly mediated by Vγ9Vδ2-T cells. Fig. 6"/>
  <result pre="6 CD137 costimulation improved the therapeutic effect of PAM on" exact="influenza" post="virus infection in vivo. a Protocol for evaluation of"/>
  <result pre="of the synergistic therapeutic effect of PAM and SA-hCD137L on" exact="influenza" post="virus-infected humanized mice. Humanized mice reconstituted with whole huPBMC"/>
  <result pre="cell-depleted huPBMC (PBMC-γδT) were infected with a sublethal dose of" exact="influenza" post="virus (25μl, 104 TCID50) intranasally (i.n.), and then treated"/>
  <result pre="c The body weight changes (b) and survival (c) of" exact="influenza" post="virus-infected humanized mice were measured at the indicated time"/>
  <result pre="robust αβ-T cell effector responses has been extensively demonstrated in" exact="infectious disease" post="models. However, the role of CD137 signaling in Vγ9Vδ2-T"/>
  <result pre="in Vγ9Vδ2-T cells remains poorly understood in the context of" exact="influenza" post="virus infection. In this study, we demonstrate for the"/>
  <result pre="ligation enhances Vγ9Vδ2-T cell proliferation, survival and antiviral activity against" exact="influenza" post="virus. The CD137+ Vγ9Vδ2-T cell population exhibited an enhanced"/>
  <result pre="CD137+ Vγ9Vδ2-T cell population exhibited an enhanced capability to treat" exact="influenza" post="when employed as an adoptive γδ-T cell therapy. Furthermore,"/>
  <result pre="protein, SA-hCD137L, could boost the effect of PAM therapy on" exact="influenza" post="by costimulating Vγ9Vδ2-T cells. Our study provides a relatively"/>
  <result pre="cells. Our study provides a relatively effective strategy to treat" exact="influenza" post="virus by targeting CD137 to improve the antiviral activity"/>
  <result pre="critical role in αβ-T cell-mediated antiviral immune responses against influenza,33,34" exact="hepatitis" post="C, cytomegalovirus, HIV, lymphocytic choriomeningitis virus, and poxviruses.35 As"/>
  <result pre="cell-mediated antiviral immune responses against influenza,33,34 hepatitis C, cytomegalovirus, HIV," exact="lymphocytic choriomeningitis" post="virus, and poxviruses.35 As shown in previous reports on"/>
  <result pre="2). Using CD137+ Vγ9Vδ2-T cells for adoptive cell-based therapy for" exact="influenza" post="is superior to using CD137− or whole Vγ9Vδ2-T cells"/>
  <result pre="CD137+ Vγ9Vδ2-T cells an attractive agent for the therapy of" exact="influenza" post="diseases. Although CD137+ Vγ9Vδ2-T cells expressed higher levels of"/>
  <result pre="mAb or SA-hCD137L during coculture of PAM-expanded Vγ9Vδ2-T cells with" exact="influenza" post="virus-infected MDMs (Fig. 4). In contrast, CD137 costimulation enhanced"/>
  <result pre="complex to induce effective antitumor immune responses.40,41 SA-mCD137L induces less" exact="lymphadenopathy" post="and splenomegaly than antibody therapy, suggesting that SA-mCD137L has"/>
  <result pre="offers a compelling alternative to anti-CD137 agonistic antibody-mediated stimulation for" exact="influenza" post="immunotherapy. Since murine T cells do not express a"/>
  <result pre="similar to that seen in humans.20,21,31,32 Moreover, we found that" exact="influenza" post="viruses could efficiently replicate and cause pathology in these"/>
  <result pre="for the study of human Vγ9Vδ2-T cell immune responses to" exact="influenza" post="viruses. Using humanized mice, we further showed the synergistic"/>
  <result pre="showed the synergistic effect of PAM and recombinant SA-hCD137L against" exact="influenza" post="virus is mediated by boosting human Vγ9Vδ2-T cell immunity."/>
  <result pre="is becoming a popular cellular immunotherapy paradigm for patients with" exact="infectious disease" post="or cancer. The potential to expand Vγ9Vδ2-T cells in"/>
  <result pre="also provides proof-of-concept data for a novel strategy for treating" exact="influenza" post="virus infection by targeting CD137 to improve the antiviral"/>
  <result pre="treatment of virus-infected humanized and Rag2−/− γc−/− mice A mouse-adapted" exact="influenza" post="H1N1 (A/PR/8/34) virus was cultured in Madin-Darby canine kidney"/>
  <result pre="For in vitro experiments, day 14-differentiated MDMs were infected with" exact="influenza" post="virus at a multiplicity of infection (MOI) of 2."/>
  <result pre="reaction (qRT-PCR) assay by targeting the conserved matrix gene of" exact="influenza" post="virus.45 A serially diluted recombinant plasmid (pET-28b(+)/M1) containing the"/>
  <result pre="target gene was used as a standard. The lungs from" exact="influenza" post="virus-infected mice were harvested at the indicated time and"/>
  <result pre="no competing interests. References References 1.BaileyESet al.The continual threat of" exact="influenza" post="virus infections at the human–animal interface: what is new"/>
  <result pre="a one health perspective?Evol. Med. Public Health2018201819219830210800 2.ZieglerTMamahitACoxNJ65 years of" exact="influenza" post="surveillance by a World Health Organization-coordinated global networkInfluenza Other"/>
  <result pre="of resistanceInfluenza Other Respir. Viruses20137253623279894 6.LeungKLipsitchMYuenKYWuJTMonitoring the fitness of antiviral-resistant" exact="influenza" post="strains during an epidemic: a mathematical modelling studyLancet Infec."/>
  <result pre="a mathematical modelling studyLancet Infec. Dis.20171733934727914853 7.HussainMet al.Drug resistance in" exact="influenza" post="A virus: the epidemiology and managementInfect. Drug Resist.20171012113428458567 8.WangBXFishENGlobal"/>
  <result pre="display potent cytotoxicity against monocyte-derived macrophages infected with human and" exact="avian influenza" post="virusesJ. Infect. Dis.200920085886519656068 17.QinGet al.Type 1 responses of human"/>
  <result pre="potent cytotoxicity against monocyte-derived macrophages infected with human and avian" exact="influenza" post="virusesJ. Infect. Dis.200920085886519656068 17.QinGet al.Type 1 responses of human"/>
  <result pre="17.QinGet al.Type 1 responses of human Vgamma9Vdelta2 T cells to" exact="influenza" post="A virusesJ. Virol.201185101091011621752902 18.QinGet al.Phenotypic and functional characterization of"/>
  <result pre="functional characterization of human gammadelta T-cell subsets in response to" exact="influenza" post="A virusesJ. Infect. Dis.20122051646165322457284 19.LiHet al.Human Vgamma9Vdelta2-T cells efficiently"/>
  <result pre="A virusesJ. Infect. Dis.20122051646165322457284 19.LiHet al.Human Vgamma9Vdelta2-T cells efficiently kill" exact="influenza" post="virus-infected lung alveolar epithelial cellsCell Mol. Immunol.20131015916423353835 20.ChenQet al.Human"/>
  <result pre="Vgamma9Vdelta2-T cells synergize CD4(+) T follicular helper cells to produce" exact="influenza" post="virus-specific antibodyFront. Immunol.2018959929670614 21.TuWet al.The aminobisphosphonate pamidronate controls influenza"/>
  <result pre="produce influenza virus-specific antibodyFront. Immunol.2018959929670614 21.TuWet al.The aminobisphosphonate pamidronate controls" exact="influenza" post="pathogenesis by expanding a gammadelta T cell population in"/>
  <result pre="Exp. Med.20112081511152221708931 22.ZhengJet al.The therapeutic effect of pamidronate on lethal" exact="avian influenza" post="A H7N9 virus infected humanized micePLoS ONE201510e013599926285203 23.SicardHet al.In"/>
  <result pre="Med.20112081511152221708931 22.ZhengJet al.The therapeutic effect of pamidronate on lethal avian" exact="influenza" post="A H7N9 virus infected humanized micePLoS ONE201510e013599926285203 23.SicardHet al.In"/>
  <result pre="nonhuman primate modelJ. Immunol.20051755471548016210655 24.ChesterCAmbulkarSKohrtHE4-1BB agonism: adding the accelerator to" exact="cancer" post="immunotherapyCancer Immunol. Immunother.2016651243124827034234 25.UnoTet al.Eradication of established tumors in"/>
  <result pre="lymphoproliferative diseaseCancer Cell.20142656557625220446 32.NiKet al.PD-1/PD-L1 Pathway mediates the alleviation of" exact="pulmonary fibrosis" post="by human mesenchymal stem cells in humanized miceAm. J."/>
  <result pre="regulates the size of the T cell memory response following" exact="influenza" post="infectionJ. Immunol.20021683777378511937529 34.LinGHet al.Endogenous 4-1BB ligand plays a critical"/>
  <result pre="therapeutic antibodiesSemin. Oncol.20103750851621074066 40.BarsoumianHBet al.A novel form of 4-1BBL prevents" exact="cancer" post="development via nonspecific activation of CD4(+) T and natural"/>
  <result pre="and monophosphoryl lipid A constitute an efficacious combination adjuvant for" exact="cancer" post="vaccinesCancer Res.2014746441645125252915 42.DieliFet al.Targeting human γδ T cells with"/>
  <result pre="cell activation is essential for virus-specific CTL activity during acute" exact="influenza" post="virus infectionCell Mol. Immunol.20181582783728413216"/>
 </snippets>
</snippetsTree>
